AEMD (Aethlon Medical) Research & Development: $0.00 Mil (TTM As of Mar. 2026)


AEMD Aethlon Medical Inc AEMD
23 GF Score
Price $1.22
! 1 Warning Sign
View Full Analysis

What is Aethlon Medical Research & Development?

Aethlon Medical AEMD -10.29% 23 Research & Development is $0.00 Mil as of Mar. 2026. GuruFocus rates AEMD with a GF Score™ of 23/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Aethlon Medical's Research & Development for the three months ended in Mar. 2026 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Aethlon Medical  (NAS:AEMD) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Aethlon Medical Research & Development Related Terms

Aethlon Medical Research & Development Historical Data

* Premium members only.

The historical data trend for Aethlon Medical's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aethlon Medical Research & Development Chart

Aethlon Medical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Aethlon Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
AEMD
23GF Score
Aethlon Medical Inc AEMD
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aethlon Medical Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.00 Mil mean?
Aethlon Medical (AEMD) has a Research & Development of $0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Aethlon Medical and its competitors.
Is Aethlon Medical's Research & Development too high?
Aethlon Medical's current Research & Development is $0.00 Mil. Overall, Aethlon Medical has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Aethlon Medical's Research & Development compare to RMSL and BTCY?
Aethlon Medical's Research & Development of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Aethlon Medical and its competitors. Aethlon Medical's current Research & Development is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aethlon Medical stock overvalued right now?
Aethlon Medical (AEMD) has a current Research & Development of $0.00 Mil. The current Research & Development is $0.00 Mil. Aethlon Medical's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Aethlon Medical (AEMD), the current Research & Development is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aethlon Medical Business Description

Address 11555 Sorrento Valley Road, Suite 203, San Diego, CA, USA, 92121
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.
23GF Score

Get the complete analysis for AEMD

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.22
Price